Biotech, Partnering, Pharma

Ligand pharma partners with Spectrum for melphalan

Posted on 15 March 2013

Tags: , ,

Ligand Pharmaceuticals pharma partners with the  signing of global license and supply agreements with Spectrum Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan.

Under the terms of the license agreement, Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestone payments.

Ligand is also eligible to receive royalties on future net sales of Captisol-enabled melphalan.

The Captisol-enabled melphalan program is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.

Spectrum, a big biotech company, will immediately assume all development of the program as a result of this license.

For further deal information visit Current Agreements (subscription required


Report: Practical Guide to Finding Partners

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply